Global Tracheal Tube and Airway Products Market, by Product Type (Products (Endotracheal Tube, Oral Airway Tube, Nasal Airway Tube, Oral/Nasal Airway Tube, Laryngoscope, Others) and Accessories), by Material (Polyvinyl Chloride (PVC), Thermoplastic Polyurethane (TPU), Silicone, Polyolefins (Polyethylene (PE) and Polypropylene (PP)), and Others), by End User (Hospitals, Ambulatory Surgical Centers, and Homecare Settings), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$ 4,140.5 Million in 2022 and is expected to exhibit a CAGR of 6.6% during the forecast period (2022-2030), as highlighted in a new report published by Coherent Market Insights.
Increasing prevalence of diseases including obstructive sleep apnea and chronic obstructive pulmonary disease is expected to drive the global tracheal tube and airway products. For instance, according to Centre for Disease Control and Prevention (CDC) data 2017, around 8.6 million people were diagnosed with chronic bronchitis and 3.4 million with emphysema in the U.S. Chronic bronchitis and emphysema are part of chronic obstructive pulmonary diseases. Furthermore, according to the data published by the Egyptian Journal of Bronchology, it is estimated to affect 10% to 30% of adults in the U.S. but in many cases goes undiagnosed. Furthermore, according to the data published by the National Center for Biotechnology Information, chronic obstructive pulmonary disease was estimated to be the sixth leading cause of death in 2019. In addition, a new American Cancer Society study published in JAMA determined that although death rates for most common diseases declined in Saudi Arabia, death rates from COPD have doubled.
Global Tracheal Tube and Airway Products Market– Impact of Coronavirus (COVID-19) Pandemic
The COVID-19 pandemic and lockdowns in various countries across the globe have impacted the financial status of businesses across all sectors, including the private healthcare sector. The COVID-19 pandemic has impacted the entire supply chain of the healthcare industry, mainly due to strict lockdown in several regions. Private healthcare is one such sector that has been impacted significantly by the COVID-19 pandemic.
However, the COVID-19 pandemic had a positive impact on the global tracheal tube and airway products market, owing to its possible association with the COVID-19 infection and increasing research and development for the tracheal tube and airway products market. For instance, according to an article published by the National Center for Biotechnology Information, a series of databases relevant to biotechnology and biomedicine, in November 2021, in the COVID 19 patients the use of tracheal tube and airway products was increased to cure and clear the obstruction in the throat and insufficient oxygen supply to the lungs. Timing of tracheostomy varied from 3 to less than 21 days, with over 90% of protocols recommending 14 days of intubation prior to tracheostomy. Most protocols advocated delaying tracheostomy until COVID-19 testing was negative. Timing of tracheostomy changes ranged from 5 to less than 30 days postoperatively, sometimes contingent on negative COVID-19 test results. Hence, demand of the tracheal tube and airway products increased during the COVID-19 pandemic.
Global Tracheal Tube and Airway Products Market: Key Developments
In January 2022, Pulmodyne Inc., an Indianapolis-based company that makes emergency airway kits, tracheostomy tubes and other respiratory management products was acquired by Intersurgical, a British maker of respiratory devices. The Pulmodyne Inc. acquisition with British maker to expand the product portfolio. Pulmodyne also sells its products to ambulance companies and hospitals for patients with asthma, congestive heart failure, chronic obstructive pulmonary disease, and other ailments.
In May 2021, Boston Scientific Corporation, a biotechnology company, on May 25 2022, it had completed CE Mark for the EXALT Model B Single-Use Bronchoscope, a single-use device designed for bedside procedures in the intensive care unit, operating room and bronchoscopy suite. The EXALT Model B Bronchoscope will be offered in three sizes – slim, regular and large – to allow for use in a wide variety of bronchoscopy procedures such as secretion management, airway intubation, percutaneous tracheostomy, double lumen endotracheal tube placement, and biopsies.